X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (875) 875
Publication (58) 58
Book Chapter (11) 11
Book Review (9) 9
Book / eBook (4) 4
Conference Proceeding (1) 1
Data Set (1) 1
Dissertation (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (280) 280
index medicus (252) 252
gastroenterology & hepatology (238) 238
gastroenterology and hepatology (165) 165
male (132) 132
female (131) 131
adult (129) 129
crohn's disease (129) 129
inflammatory-bowel-disease (122) 122
ulcerative colitis (120) 120
crohn disease - drug therapy (111) 111
inflammatory bowel disease (106) 106
middle aged (106) 106
treatment outcome (101) 101
infliximab (99) 99
clinical trials (86) 86
therapy (83) 83
severity of illness index (79) 79
maintenance therapy (75) 75
crohns-disease (69) 69
double-blind (69) 69
double-blind method (69) 69
abridged index medicus (68) 68
colitis, ulcerative - drug therapy (66) 66
ulcerative-colitis (61) 61
antibodies, monoclonal - therapeutic use (60) 60
care and treatment (57) 57
remission induction (57) 57
aged (53) 53
gastrointestinal agents - therapeutic use (53) 53
medicine, general & internal (49) 49
analysis (48) 48
remission (46) 46
pharmacology & pharmacy (45) 45
efficacy (44) 44
patients (43) 43
crohns disease (42) 42
certolizumab pegol (38) 38
gastroenterology (38) 38
randomized controlled trials as topic (38) 38
tumor necrosis factor-alpha - antagonists & inhibitors (38) 38
adolescent (37) 37
young adult (37) 37
immunosuppressive agents - therapeutic use (36) 36
drug therapy (34) 34
induction (34) 34
quality of life (34) 34
endoscopy (32) 32
medical research (32) 32
monoclonal antibodies (32) 32
adalimumab (31) 31
antibodies, monoclonal, humanized - therapeutic use (31) 31
safety (29) 29
anti-inflammatory agents - therapeutic use (28) 28
inflammatory bowel diseases - drug therapy (28) 28
placebo-controlled trial (28) 28
activity index (27) 27
clinical-trials (26) 26
gastrointestinal agents - adverse effects (26) 26
ibd (26) 26
c-reactive protein (25) 25
gastrointestinal diseases (25) 25
management (25) 25
quality-of-life (25) 25
research (24) 24
antibodies, monoclonal - administration & dosage (23) 23
antibodies, monoclonal - adverse effects (23) 23
drug therapy, combination (23) 23
inflammatory bowel diseases (23) 23
vedolizumab (23) 23
azathioprine (21) 21
crohn’s disease (21) 21
diagnosis (21) 21
induction therapy (21) 21
medicine, experimental (21) 21
reproducibility of results (21) 21
rheumatoid-arthritis (21) 21
colitis, ulcerative - pathology (20) 20
crohn disease - diagnosis (20) 20
crohn disease - therapy (20) 20
dose-response relationship, drug (20) 20
medicine & public health (20) 20
pharmacokinetics (20) 20
prognosis (20) 20
studies (20) 20
tumor necrosis factor-tnf (20) 20
antibodies, monoclonal, humanized (19) 19
gastrointestinal agents - administration & dosage (19) 19
inflammation (19) 19
maintenance (19) 19
colonoscopy (18) 18
corticosteroids (18) 18
crohn disease - pathology (18) 18
tumor necrosis factor (18) 18
aged, 80 and over (17) 17
algorithms (17) 17
health aspects (17) 17
surgery (17) 17
trial (17) 17
validation (17) 17
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2015, Volume 386, Issue 10006, pp. 1825 - 1834
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2013, Volume 369, Issue 8, pp. 711 - 721
Journal Article
Gastroenterology and Hepatology, ISSN 1554-7914, 04/2018, Volume 14, Issue 4, pp. 244 - 246
Journal Article
Gastroenterology and Hepatology, ISSN 1554-7914, 12/2017, Volume 13, Issue 12, pp. 745 - 747
Journal Article
Lancet, The, ISSN 0140-6736, 2017, Volume 389, Issue 10080, pp. 1699 - 1709
Summary Background The interleukin-23 pathway is implicated genetically and biologically in the pathogenesis of Crohn's disease. We aimed to assess the... 
Internal Medicine | TRIAL | CELLS | MEDICINE, GENERAL & INTERNAL | ANTI-TNF | INFLAMMATORY-BOWEL-DISEASE | EFFICACY | ULCERATIVE-COLITIS | NECROSIS-FACTOR ANTAGONISTS | ANTITUMOR | MAINTENANCE THERAPY | FACTOR-ALPHA | Severity of Illness Index | Interleukin-23 Subunit p19 - antagonists & inhibitors | Double-Blind Method | Drug Administration Schedule | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Gastrointestinal Agents - administration & dosage | Antibodies, Monoclonal - therapeutic use | Male | Treatment Outcome | Remission Induction | Dose-Response Relationship, Drug | Young Adult | Antibodies, Monoclonal - administration & dosage | Crohn Disease - drug therapy | Adolescent | Gastrointestinal Agents - therapeutic use | Adult | Female | Aged | Gastrointestinal Agents - adverse effects | Clinical trials | Monoclonal antibodies | Medicine, Experimental | Medical research | Interleukins | Intravenous administration | Pathogenesis | Mucosa | Interleukin | Interleukin 23 | Antagonists | Evidence-based medicine | Intravenous therapy | Randomization | Endoscopes | Motivation | Gastroenterology | Remission | Tumor necrosis factor-TNF | Colon | Safety | Active control | Chronic illnesses | Psoriasis | Cytokines | Ileitis | Nausea | Inflammation | Crohn's disease | Disease control | Patients | Ileum | Crohns disease | Inflammatory bowel disease | Interactive systems | Tumor necrosis factor | Ulcers | TNF inhibitors | Tumors
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 04/2019, Volume 78, Issue 4, pp. 473 - 479
ObjectivesHere, we present the reported incidence rates of inflammatory bowel disease (IBD) in patients receiving treatment with secukinumab for psoriasis... 
Crohn's disease | ulcerative colitis | inflammatory bowel disease | secukinumab | EXTRAARTICULAR MANIFESTATIONS | CROHNS-DISEASE | ACTIVE RHEUMATOID-ARTHRITIS | PLAQUE PSORIASIS | ULCERATIVE-COLITIS | GUT INFLAMMATION | PHASE-III | DOUBLE-BLIND | TNF-ALPHA THERAPY | RHEUMATOLOGY | GENOME-WIDE ASSOCIATION | Crohn Disease - epidemiology | Antibodies, Monoclonal, Humanized - adverse effects | Arthritis, Psoriatic - epidemiology | Risk Assessment - methods | Antibodies, Monoclonal, Humanized - therapeutic use | Psoriasis - drug therapy | Randomized Controlled Trials as Topic - methods | Humans | Spondylitis, Ankylosing - drug therapy | Colitis, Ulcerative - epidemiology | Incidence | Psoriasis - epidemiology | Inflammatory Bowel Diseases - epidemiology | Colitis, Ulcerative - chemically induced | Crohn Disease - chemically induced | Arthritis, Psoriatic - drug therapy | Spondylitis, Ankylosing - epidemiology | Product Surveillance, Postmarketing | Biological Products - adverse effects | Inflammatory Bowel Diseases - chemically induced | Retrospective Studies | Biological Products - therapeutic use | Inflammatory bowel diseases | Psoriasis | Cytokines | Comorbidity | Clinical trials | Data processing | Genomes | Arthritis | Inflammation | Patients | Inflammatory diseases | Studies | Inflammatory bowel disease | Spondylitis | Surveillance | Intestine | Rheumatoid arthritis | Tumor necrosis factor-TNF | Ankylosing spondylitis | Ulcerative colitis | 2311 | Spondyloarthritis | 1506 | crohn’s disease
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9940, pp. 309 - 318
Journal Article
Gastroenterology and Hepatology, ISSN 1554-7914, 09/2016, Volume 12, Issue 9, pp. 572 - 574
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2013, Volume 369, Issue 8, pp. 699 - 710
Journal Article